Umbilical Cord Blood Cell Infusion
Myelodysplastic Syndrome
Weill Medical College of Cornell UniversityCell therapyPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
108 Active assets in the Myelodysplastic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Thiotepa Sawa Ito, MD | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Cladribine University of Florida | Phase 2/3 | BB |
Treosulfan Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
Clofarabine Memorial Sloan Kettering Cancer Center | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Umbilical Cord Blood Cell Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →